The Mechanisms of Resistance to Tyrosine Kinase Inhibitor Imatinib Therapy of Chronic Myeloid Leukemia

The Mechanisms of Resistance to Tyrosine Kinase Inhibitor Imatinib Therapy of Chronic Myeloid Leukemia

Imatinib mesylate is a potent and high selective inhibitor of Bcr-Abl tyrosine kinase, which is established now as the standard of Philadelphia chromosome positive (Ph) chronic myeloid leukemia (CML) treatment. The treatment of patients with chronic phase of CML with imatinib has resulted in high ra...

Full description

Saved in:
Bibliographic Details
Main Authors: S. I. Kutsev, S. V. Mordanov, A. N. Zeltser, O. S. Oxenjuk, O. A. Ustaeva, T. I. Kungurova, E. V. Burnasheva, E. Grankina, Yu. V. Shatokhin
Format: Article
Language:English
Published: State Budget Educational Institute of Higher Professional Education, Rostov State Medical University, Ministry Health of Russian Federation 2010-06-01
Series:Медицинский вестник Юга России
Subjects:
chronic myeloid leukemia
tyrosine kinase inhibitors
mechanisms of resistance
Online Access:https://www.medicalherald.ru/jour/article/view/1253
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items